Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001

Biochemical Pharmacology

Volumn 83, Issue 4, 2012, Pages 480-488

  Loehberg, Christian R ^a   Strissel, Pamela L ^a   Dittrich, Ralf ^a   Strick, Reiner ^a   Dittmer, Juergen ^b   Dittmer, Angela ^b   Fabry, Ben ^c   Kalender, Willi A ^c   Koch, Thorsten ^c   Wachter, David L ^a   Groh, Nicole ^a   Polier, Astrid ^a   Brandt, Ina ^a   Lotz, Laura ^a   Hoffmann, Inge ^a   Koppitz, Florentine ^a   Oeser, Sonja ^a   Mueller, Andreas ^a   Fasching, Peter A ^a   Lux, Michael P ^a   Beckmann, Matthias W ^a   Schrauder, Michael G ^a   more..

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Breast cancer; Chloroquine; mTOR; p53; RAD001

Indexed keywords

CHLOROQUINE; COLLAGEN; EVEROLIMUS; MATRIX PROTEIN; PROTEIN KINASE B; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEIN V-AKT; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855819195     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.022     Document Type: Article

References (55)

1. C.T. Keith, and S.L. Schreiber PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints Science 270 1995 50 51
2. T. Schmelzle, and M.N. Hall TOR, a central controller of cell growth Cell 103 2000 253 262
3. M.A. Bjornsti, and P.J. Houghton The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 2004 335 348 (Pubitemid 38579480)
4. R.J. Shaw, and L.C. Cantley Ras, PI(3)K and mTOR signalling controls tumour cell growth Nature 441 2006 424 430 (Pubitemid 44050136)
5. N. Pullen, and G. Thomas The modular phosphorylation and activation of p70s6k FEBS Lett 410 1997 78 82
6. Q.P. Weng, M. Kozlowski, C. Belham, A. Zhang, M.J. Comb, and J. Avruch Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies J Biol Chem 273 1998 16621 16629 (Pubitemid 28311452)
7. A. O'Donnell, S. Faivre, H.A. Burris 3rd, D. Rea, V. Papadimitrakopoulou, and N. Shand Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors J Clin Oncol 26 2008 1588 1595
8. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, and D. Smith mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 66 2006 1500 1508 (Pubitemid 43259931)
9. S.Y. Sun, L.M. Rosenberg, X. Wang, Z. Zhou, P. Yue, and H. Fu Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition Cancer Res 65 2005 7052 7058 (Pubitemid 41161231)
10. J. Tabernero, F. Rojo, E. Calvo, H. Burris, I. Judson, and K. Hazell Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors J Clin Oncol 26 2008 1603 1610
11. S. Huang, and P.J. Houghton Targeting mTOR signaling for cancer therapy Curr Opin Pharmacol 3 2003 371 377 (Pubitemid 36908940)
12. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L.J. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 2006
13. M. Breuleux, M. Klopfenstein, C. Stephan, C.A. Doughty, L. Barys, and S.M. Maira Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition Mol Cancer Ther 8 2009 742 753
14. D.E. Martin, and M.N. Hall The expanding TOR signaling network Curr Opin Cell Biol 17 2005 158 166 (Pubitemid 40380939)
15. X. Wang, P. Yue, Y.A. Kim, H. Fu, F.R. Khuri, and S.Y. Sun Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation Cancer Res 68 2008 7409 7418
16. M.P. Scheid, M. Parsons, and J.R. Woodgett Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation Mol Cell Biol 25 2005 2347 2363 (Pubitemid 40354630)
17. C.R. Loehberg, T. Thompson, M.B. Kastan, K.H. Maclean, D.G. Edwards, and F.S. Kittrell Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis Cancer Res 67 2007 12026 12033
18. T.M. Gottlieb, J.F. Leal, R. Seger, Y. Taya, and M. Oren Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis Oncogene 21 2002 1299 1303 (Pubitemid 34185247)
19. Y. Ogawara, S. Kishishita, T. Obata, Y. Isazawa, T. Suzuki, and K. Tanaka Akt enhances Mdm2-mediated ubiquitination and degradation of p53 J Biol Chem 277 2002 21843 21850 (Pubitemid 34952337)
20. C. Hu, V.R. Solomon, G. Ulibarri, and H. Lee The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine Bioorg Med Chem 16 2008 7888 7893
21. C. Hu, V. Raja Solomon, P. Cano, and H. Lee A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells Eur J Med Chem 45 2010 705 709
22. S.M. Shafie, and L.A. Liotta Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice Cancer Lett 11 1980 81 87 (Pubitemid 11179857)
23. I.B. Runnebaum, M. Nagarajan, M. Bowman, D. Soto, and S. Sukumar Mutations in p53 as potential molecular markers for human breast cancer Proc Natl Acad Sci USA 88 1991 10657 10661 (Pubitemid 21915896)
24. I. Wacker, M. Sachs, K. Knaup, M. Wiesener, J. Weiske, and O. Huber Key role for activin B in cellular transformation after loss of the von Hippel-Lindau tumor suppressor Mol Cell Biol 29 2009 1707 1718
25. C.T. Mierke, P. Kollmannsberger, D.P. Zitterbart, G. Diez, T.M. Koch, and S. Marg Vinculin facilitates cell invasion into three-dimensional collagen matrices J Biol Chem 285 2010 13121 13130
26. A. Dittmer, D. Schunke, and J. Dittmer PTHrP promotes homotypic aggregation of breast cancer cells in three-dimensional cultures Cancer Lett 260 2008 56 61
27. A. Dittmer, K. Hohlfeld, J. Lutzkendorf, L.P. Muller, and J. Dittmer Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10 Cell Mol Life Sci 66 2009 3053 3065
28. K. VanWeelden, L. Flanagan, L. Binderup, M. Tenniswood, and J. Welsh Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089 Endocrinology 139 1998 2102 2110 (Pubitemid 28513874)
29. M. Degtyarev, A. De Maziere, C. Orr, J. Lin, B.B. Lee, and J.Y. Tien Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents J Cell Biol 183 2008 101 116
30. L. Fu, Y.A. Kim, X. Wang, X. Wu, P. Yue, and S. Lonial Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy Cancer Res 69 2009 8967 8976
31. C. Bellodi, M.R. Lidonnici, A. Hamilton, G.V. Helgason, A.R. Soliera, and M. Ronchetti Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells J Clin Invest 119 2009 1109 1123
32. P.L. Strissel, S. Ellmann, E. Loprich, F. Thiel, P.A. Fasching, and E. Stiegler Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen Int J Cancer 123 2008 2871 2879
33. A. Dittmer, A. Fuchs, I. Oerlecke, B. Leyh, S. Kaiser, and J.W. Martens Mesenchymal stem cells and carcinoma-associated fibroblasts sensitize breast cancer cells in 3D cultures to kinase inhibitors Int J Oncol 39 2011 689 696
34. A. Koff, M. Ohtsuki, K. Polyak, J.M. Roberts, and J. Massague Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta Science 260 1993 536 539 (Pubitemid 23161617)
35. B.T. Nave, M. Ouwens, D.J. Withers, D.R. Alessi, and P.R. Shepherd Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation Biochem J 344 Pt 2 1999 427 431 (Pubitemid 30011599)
36. C. Reinhard, G. Thomas, and S.C. Kozma A single gene encodes two isoforms of the p70 S6 kinase: activation upon mitogenic stimulation Proc Natl Acad Sci USA 89 1992 4052 4056
37. J. Baselga, V. Semiglazov, P. van Dam, A. Manikhas, M. Bellet, and J. Mayordomo Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2009 2630 2637
38. O. Gluz, C. Liedtke, U. Nitz, and N. Harbeck Molekulare Mechanismen der Chemoresistenz und Moeglichkeiten der Überwindung Geburtsh Frauenheilk 69 2009 138 144
39. E. Appella, and C.W. Anderson Post-translational modifications and activation of p53 by genotoxic stresses Eur J Biochem 268 2001 2764 2772 (Pubitemid 32862957)
40. R.T. Abraham Cell cycle checkpoint signaling through the ATM and ATR kinases Genes Dev 15 2001 2177 2196 (Pubitemid 32843830)
41. M.B. Kastan, and D.S. Lim The many substrates and functions of ATM Nat Rev Mol Cell Biol 1 2000 179 186
42. C.S. Sorensen, R.G. Syljuasen, J. Falck, T. Schroeder, L. Ronnstrand, and K.K. Khanna Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A Cancer Cell 3 2003 247 258 (Pubitemid 37443880)
43. J. Falck, N. Mailand, R.G. Syljuasen, J. Bartek, and J. Lukas The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis Nature 410 2001 842 847 (Pubitemid 32303786)
44. M.E. Fedorko, J.G. Hirsch, and Z.A. Cohn Autophagic vacuoles produced in vitro. II. Studies on the mechanism of formation of autophagic vacuoles produced by chloroquine J Cell Biol 38 1968 392 402
45. F. Janku, D.J. McConkey, D.S. Hong, and R. Kurzrock Autophagy as a target for anticancer therapy Nat Rev Clin Oncol 8 2011 528 539
46. S.R. Meshnick Chloroquine as intercalator: a hypothesis revived Parasitol Today 6 1990 77 79
47. W.A. Krajewski Alterations in the internucleosomal DNA helical twist in chromatin of human erythroleukemia cells in vivo influences the chromatin higher-order folding FEBS Lett 361 1995 149 152
48. W.A. Krajewski Effect of in vivo histone hyperacetylation on the state of chromatin fibers J Biomol Struct Dyn 16 1999 1097 1106 (Pubitemid 29210735)
49. W.A. Krajewski, M.A. Lagarkova, N.P. Sharova, S.D. Stolyarov, and J. Ausio Analysis of chromatin structural transitions by means of intercalator dyes Dokl Biochem Biophys 378 2001 150 152
50. C.H. Lu, S.L. Wyszomierski, L.M. Tseng, M.H. Sun, K.H. Lan, and C.L. Neal Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency Clin Cancer Res 13 2007 5883 5888 (Pubitemid 47583915)
51. M.I. Torres-Arzayus, J. Yuan, J.L. DellaGatta, H. Lane, A.L. Kung, and M. Brown Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland Cancer Res 66 2006 11381 11388 (Pubitemid 46009969)
52. R.I. Rynes Antimalarial drugs in the treatment of rheumatological diseases Br J Rheumatol 36 1997 799 805
53. G. Dontu, W.M. Abdallah, J.M. Foley, K.W. Jackson, M.F. Clarke, and M.J. Kawamura In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells Genes Dev 17 2003 1253 1270 (Pubitemid 36583168)
54. M.A. dit Faute, L. Laurent, D. Ploton, M.F. Poupon, J.C. Jardillier, and H. Bobichon Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant Clin Exp Metastasis 19 2002 161 168 (Pubitemid 34264086)
55. S.K. Muthuswamy, D. Li, S. Lelievre, M.J. Bissell, and J.S. Brugge ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini Nat Cell Biol 3 2001 785 792 (Pubitemid 32842683)